Neurol. pro Praxi, 2006; 1: 32-35

Léčba počátečního stadia Parkinsonovy nemoci

prof. MUDr. Petr Kaňovský, CSc.1, MUDr. Igor Nestrašil3,2, MUDr. Martin Nevrlý1, MUDr. Pavel Ressner5,4
1 Neurologická klinika FN a LF UP Olomouc
2 I. neurologická klinika LF MU a FN u sv. Anny Brno
3 Neurologická ambulance, Masarykův onkologický ústav, Brno
4 Centrum pro diagnostiku a léčbu extrapyramidových onemocnění a kognitivních poruch
5 Neurologická klinika FNsP Ostrava-Poruba

V počátečním stadiu Parkinsonovy nemoci je zásadní především zvolit okamžik, kdy je medikamentózní terapie zahájena. Mělo by tak být učiněno ve chvíli, kdy projevy nemoci významněji omezují běžné denní aktivity pacienta. Následně je pak třeba zvolit některý z několika druhů preparátů, které jsou pro léčbu tohoto stadia Parkinsonovy nemoci dostupné. V zásadě je vždy vhodné začít léčbu inhibitory MAO-B nebo antiglutamátergními preparáty. Je-li symptomatologie výraznější, je nezbytná dopaminergní terapie. Konsenzus z posledních let, podpořený výsledky klinických studií, je ten, že v takovém případě by léčba měla být zahájena preparátem ze skupiny agonistů dopaminu.

Keywords: Klíčová slova: Parkinsonova nemoc, počáteční stadium, terapie, agonisté dopaminu.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kaňovský P, Nestrašil I, Nevrlý M, Ressner P. Léčba počátečního stadia Parkinsonovy nemoci. Neurol. praxi. 2006;7(1):32-35.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Baas HK, Schueler P. Efficacy of cabergoline in long-term use: results of three observational studies in 1500 patients with Parkinson´s disease. Eur Neurol 2001, 46 (Suppl. 1): 18-23. Go to original source... Go to PubMed...
    2. Bonuccelli U, Colzi, A, Del Dotto P. Pergolide in the treatment of patiens with early and advanced Parkinson´s disease. Clin Neuropharmacol 2002, 25: 1-10. Go to original source... Go to PubMed...
    3. Brucke T, Danielczyk W, Simanyi M, Sofic E, Riederer P. Terguride: partial dopamine agonist in the treatment of Parkinson´s disease. Adv Neurol 1987, 45: 573-576.
    4. Goetz, CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatmens of Parkinson´s disease: 2001 to 2004. Mov Disord 2005, 20: 523-539. Go to original source... Go to PubMed...
    5. Homann CN, Wenzel K, Suppan K, Ivanic G, Kriechbaum N, Crevenna R, Ott E. Slep attacks in patiens taking dopamine agonists: review. BMJ 2002, 324: 1483-1487. Go to original source... Go to PubMed...
    6. Horstink M, Tolosa E, Bonuccelli U, Deuschl G, Kanovsky, P, Friedman A, Larsen JP, Lees A, Oertel W, Poewe W, Rascol P, Sampaio C. Review of the management of Parkinson´s disease. Report of an EFNS/MDS-ES Task Force. Eur J Neurol, in press.
    7. Jost WH. Ropinirole: current status of the studies. J Neurol 2004 (Suppl. 6): 13-18. Go to original source... Go to PubMed...
    8. Lees AJ. Alternatives to levodopa in the initial treatment of early Parkinson´s disease. Druha Aging 2005, 22: 731-740. Go to original source... Go to PubMed...
    9. Moeller J, Oertel WH. Pramipexole in the treatment of Parkinson´s disease: new developments. Expert Rev Neurother 2005, 5: 581-586. Go to original source... Go to PubMed...
    10. Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson´s disease. Arch Neurol 1989, 46: 1052-1060. Go to original source... Go to PubMed...
    11. Ponsford JR. Treatment of early onset Parkinson´s disease with ropinirole. J Neurol Neurosurg Psychiatry 2001, 70: 418-419. Go to original source... Go to PubMed...
    12. Poewe W, Sampaio C, Oertel WH, Rascol O. DA agonists - ergot derivatives: bromocriptine: management of Parkinson´s disease. Mov Disored 2002, 17 (suppl 4): 53-67. Go to original source... Go to PubMed...
    13. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patiens with early Parkinson´s disease, who were treated woth ropinirole or levodopa. 056 study group. N Engl J Med 2000, 342: 1484-1491. Go to original source... Go to PubMed...
    14. Schapira AH. Present and future drug treatment for Parkinson´s disease. J Neurol Neurosurg Psychiatry 2005, 76: 1472-1478. Go to original source... Go to PubMed...
    15. Van Camp G, Flamez A, Cosyns B, Goldstein J, Perdaens C, Schoors D. Heart valvular disease in patiens with Parkinson´s disease treated with high-dose pergolide. Neurology 2003, 61: 859-861. Go to original source... Go to PubMed...
    16. Whone AL, Watts RL, Stoessl J, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ, REAL-PET study group. Slower progression of Parkinson´s disease with ropinirole versus levodopa: the REAL-PET study. Ann Neurol 2003, 54: 93-101. Go to original source... Go to PubMed...
    17. Woitalla D, Miller T, Benz S, Horowski R, Przuntek H. Transdermal lisuride delivery in the treatment of Parkinson´s disease. J Neural Transm Suppl. 2004, 68: 89-95. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.